Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics

dc.contributor.authorMartínez-Clemente, José
dc.contributor.authorLópez Arnau, Raúl
dc.contributor.authorCarbó Banús, Marcel·lí
dc.contributor.authorPubill Sánchez, David
dc.contributor.authorCamarasa García, Jordi
dc.contributor.authorEscubedo Rafa, Elena
dc.date.accessioned2014-05-13T10:56:02Z
dc.date.available2014-05-13T10:56:02Z
dc.date.issued2013-05-07
dc.date.updated2014-05-13T10:56:02Z
dc.descriptionFe d'errates disponible a: http://​dx.​doi.​org/​10.​1007/​s00213-013-3283-6
dc.description.abstractRationale Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, alternative to ecstasy or cocaine. Objective The major aims were to investigate the pharmacokineticsa and locomotor activity of mephedrone in rats and provide a pharmacokinetic/pharmacodynamic model. Methods Mephedrone was administered to male Sprague-Dawley rats intravenously (10 mg/kg) and orally (30 and 60 mg/kg). Plasma concentrations and metabolites were characterized using LC/MS and LC-MS/MS fragmentation patterns. Locomotor activity was monitored for 180-240 min. Results Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α=10.23 h−1, β=1.86 h−1). After oral administration, peak mephedrone concentrations were achieved between 0.5 and 1 h and declined to undetectable levels at 9 h. The absolute bioavailability of mephedrone was about 10 % and the percentage of mephedrone protein binding was 21.59±3.67%. We have identified five phase I metabolites in rat blood after oral administration. The relationship between brain levels and free plasma concentration was 1.85±0.08. Mephedrone induced a dose-dependent increase in locomotor activity, which lasted up to 2 h. The pharmacokinetic-pharmacodynamic model successfully describes the relationship between mephedrone plasma concentrations and its psychostimulant effect. Conclusions We suggest a very important first-pass effect for mephedrone after oral administration and an easy access to the central nervous system. The model described might be useful in the estimation and prediction of the onset, magnitude,and time course of mephedrone pharmacodynamics as well as to design new animal models of mephedrone addiction and toxicity.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec622132
dc.identifier.issn0033-3158
dc.identifier.urihttps://hdl.handle.net/2445/53992
dc.language.isoeng
dc.publisherSpringer Verlag
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1007/s00213-013-3108-7
dc.relation.ispartofPsychopharmacology, 2013, vol. 229, num. 2, p. 295-306
dc.relation.urihttp://dx.doi.org/10.1007/s00213-013-3108-7
dc.relation.urihttp://​dx.​doi.​org/​10.​1007/​s00213-013-3283-6
dc.rights(c) Springer Verlag, 2013
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationAmfetamines
dc.subject.classificationSistema nerviós central
dc.subject.classificationCervell
dc.subject.classificationFarmacocinètica
dc.subject.classificationEfectes fisiològics
dc.subject.classificationDrogues de disseny
dc.subject.otherAmphetamines
dc.subject.otherCentral nervous system
dc.subject.otherBrain
dc.subject.otherPharmacokinetics
dc.subject.otherPhysiological effect
dc.subject.otherDesigner drugs
dc.titleMephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
622132.pdf
Mida:
303.84 KB
Format:
Adobe Portable Document Format